3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
117
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
15
Ovarian Neoplasms
5
Brain Neoplasms
4
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Sarcoma
2
Recurrence
2
Prostatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Breast Cancer
2
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Metastatic HER2-positive Breast Cancer
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Lung Neoplasms
1
Ketosis
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
HR+HER2- Breast Cancer
1
HR Positive HER2 Negative Advanced Breast Cancer
1
HER2-negative Metastatic Breast Cancer
1
Interventions
Capecitabine
3
tucatinib
2
Trastuzumab
2
Methotrexate
2
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
eribulin
×
Breast
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled